
Septerna Inc (SEPN) Stock Forecast & Price Target
Septerna Inc (SEPN) Analyst Ratings
Bulls say
Septerna Inc. demonstrates significant upside potential in its stock, with a current enterprise value of approximately $430 million, and projections indicating an 8-10x increase in share price contingent upon a successful partnership with Novo. The company's pipeline, particularly candidates like SEP-631, has the potential to achieve blockbuster status comparable to drugs generating billions in annual sales, thereby underscoring a strong commercial opportunity in the obesity treatment market. Additionally, Septerna's innovative Native Complex Platform and its focus on diverse therapeutic areas suggest robust long-term value creation, enhancing investor confidence in the company's future growth prospects.
Bears say
Septerna Inc. faces several fundamental risks that contribute to a negative outlook on its stock, primarily revolving around potential delays in the clinical development of key candidates such as SEP-631. The company's reliance on strategic partnerships, particularly with Novo Nordisk, raises concerns regarding collaboration stability and future product market penetration. Additionally, the prospect of long-term dilution risk further complicates the financial landscape, as there may be challenges in achieving regulatory approvals and overcoming setbacks in clinical trials.
This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.
Septerna Inc (SEPN) Analyst Forecast & Price Prediction
Start investing in Septerna Inc (SEPN)
Order type
Buy in
Order amount
Est. shares
0 shares